Lake Bleu Capital

Lake Bleu Capital, a Hong Kong-based asset management firm, specializes in healthcare investments across Asia, particularly Greater China. It targets mid-to-late-stage opportunities in pharmaceuticals, biotech, medical devices, and healthcare services, employing a value-creating strategy driven by bottom-up research. The firm manages a multi-billion dollar AUM platform, reported at US$2 billion in 2021, with a team of 21-50 employees overseeing 5 hedge funds and 2 closed funds. Notable investments include leading AffaMed Therapeutics' US$170 million+ Series B financing and holding approximately 18 million shares in Zylox-Tonbridge Medical Technology. Key personnel include Bin Li, Amanda Haixi Li, Ran Huo, and Tony Ding. Lake Bleu Capital was established in 2019 by founder Bin Li. Its business model centers on manages hedge funds and private equity funds focused on healthcare, earns through asset management fees and performance incentives.